HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

By BioPharma Dive · Apr 22, 2026 · via BioPharma Dive
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

Image: BioPharma Dive

Tags
pipelineformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
PipelineFiercePharma ↗
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his…
Apr 25, 2026
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
PipelineFiercePharma ↗
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.…
Apr 23, 2026
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
PipelineFierceBiotech ↗
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Apr 23, 2026